Abstracts tagged "Behcet’s syndrome"

Abstract Number: 2967 • 2016 ACR/ARHP Annual Meeting
Identifying Core Domains for BehçEt’s Syndrome Trials: An International Physician and Patient Delphi Exercise
Alexa Meara¹, Yesim Ozguler², Alfred Mahr³, Haner Direskeneli⁴, Ahmet Gul⁵, Yusuf Yazici⁶, Hasan Yazici², Peter A. Merkel⁷ and Gulen Hatemi², ¹Internal Medicine/Rheumatology, The Ohio State University, Columbus, OH, ²Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ³Hospital Saint-Louis, Paris, France, ⁴Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey, ⁵Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ⁶Rheumatology, New York University Medical Center, La Jolla, CA, ⁷Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: An unmet need for reliable, validated, and widely accepted outcome measures for trials in BehetÕs syndrome (BS) was identified through: i) a systematic review;…
Abstract Number: 879 • 2016 ACR/ARHP Annual Meeting
Associated Inflammatory Diseases in Takayasu’s Arteritis: The Many Faces of a Disease
Sinem Nihal Esatoglu¹, Ayse Merve Celik², Didar Ucar³, Aykut Ferhat Celik⁴, Serdal Ugurlu⁵, Gulen Hatemi⁵, Melike Melikoglu⁵, Izzet Fresko⁵, Vedat Hamuryudan⁵, Huri Ozdogan⁶, Sebahattin Yurdakul⁵, Hasan Yazici⁵ and Emire Seyahi⁵, ¹Rheumatology, Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey, ³Istanbul University, Cerrahpasa Medical Faculty, Department of Ophthalmology, Istanbul, Turkey, ⁴Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Gastroenterology, Istanbul, Turkey, ⁵Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ⁶Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey
Background/Purpose: Case reports and series suggest that Takayasu’s arteritis (TA) can co-exist with various inflammatory disorders. Inflammatory bowel disease [(IBD; Crohn's disease (CD) or ulcerative…
Abstract Number: 2978 • 2016 ACR/ARHP Annual Meeting
Psychiatric Involvement and Behcet’S Syndrome: Does Bipolar Disorder Represent a Clinical Feature of the Disease?
Rosaria Talarico¹, Elena Elefante², Laura Palagini³, Anna d'Ascanio⁴, Chiara Stagnaro⁴, Chiara Tani⁴, Chiara Baldini⁴, Rossella Neri¹ and Marta Mosca⁴, ¹Rheumatology Unit, University of Pisa, PISA, Italy, ²RHEUMATOLOGY UNIT, University of Pisa, Pisa, Italy, ³Psychiatric Unit, University, PISA, Italy, ⁴Rheumatology Unit, University of Pisa, Pisa, Italy
Background/Purpose: Frequency of psychiatric disorders in Behçet’s syndrome (BS) is a debated issue: while some experts attribute their presence to the chronicity of the illness,…
Abstract Number: 1202 • 2016 ACR/ARHP Annual Meeting
Characteristic Compositional and Functional Alteration of Gut Microbiota in Patients with Behcet’s Disease
Noboru Suzuki¹, Jun Shimizu² and Takao Kubota³, ¹Department of Immunology and medicine, St. Marianna University School of Medicine, Kawasaki-shi, 216-8511, Japan, ²Department of Immunology and Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ³The Japan Self Defense Forces Central Hospital, Tokyo, Japan
Background/Purpose: We have presented evidence that the frequency of helper T (Th)17 cells increased and the cells had already been activated in vivo in patients…
Abstract Number: 2979 • 2016 ACR/ARHP Annual Meeting
a Systematic Literature Review on the Treatment of Skin, Mucosa and Joint Involvement of BehçEt’s Syndrome Informing the Eular Recommendations for the Management of BehçEt’s Syndrome
Pietro Leccese¹, Yesim Ozguler², Robin Christensen³, Sinem Nihal Esatoglu⁴, Dongsik Bang⁵, Bahram Bodaghi⁶, Aykut Ferhat Celik⁷, Farida Fortune⁸, Julien Gaudric⁹, Ahmet Gul¹⁰, Ina Kotter¹¹, Alfred Mahr¹², Robert J Moots¹³, Ignazio Olivieri¹⁴, Jutta Richter¹⁵, David Saadoun¹⁶, Carlo Salvarani¹⁷, Frances Scuderi¹⁸, PETROS P SFIKAKIS¹⁹, Aksel Siva²⁰, Miles Stanford²¹, Ilknur Tugal-tutkun²², Richard West²³, Sebahattin Yurdakul², Hasan Yazici² and Gulen Hatemi², ¹Rheumatology, Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Matera, Italy, Matera, Italy, ²Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ³The Parker instutute, RC, Copenhagen, Denmark, ⁴Rheumatology, Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ⁵Department of Dermatology, Severance Hospital, Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Korea, Seoul, Korea, The Democratic People's Republic of, ⁶Ophthalmology, Pierre and Marie Curie University - Paris 6 Paris, France, Paris, France, ⁷Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Gastroenterology, Istanbul, Turkey, ⁸Dental Institute, Barts and The London NHS Trust, London, United Kingdom, ⁹Department of Vascular surgery GHPS, Paris, France, ¹⁰Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ¹¹Internal Medicine, Robert-Bosch-Hospital, Stuttgart, Germany, ¹²Hospital Saint-Louis, Paris, France, ¹³Academic Rheumatology Unit, University of Liverpool, Liverpool, United Kingdom, ¹⁴U.O. Reumatologia, A.O. Ospedale San Carlo, Potenza, Italy, ¹⁵Tubingen University, Tubingen, Germany, ¹⁶Department of Internal Medicine and Clinical Immunology, AP-HP Pitié-Salpêtrière Hospital, Paris, France, ¹⁷Rheumatology Unit, Arcispedale S Maria Nuova, IRCCS, Reggio Emilia, Italy, ¹⁸Patient partner, Catania, Italy, ¹⁹First Department of Propedeutic Internal Medicine, Laikon Hospital, Athens University Medical School, Athens, Greece, ²⁰Department of Neurology, Istanbul University, Cerrahpasa Medical Faculty, Department of Neurology, Istanbul, Turkey, ²¹Ophthalmology, Guy's and St. Thomas' Hospital, London, United Kingdom, ²²Department of Ophthalmology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey, ²³Patient partner, London, United Kingdom
A Systematic Literature Review on the Treatment of Skin, Mucosa and Joint Involvement of Behçet’s Syndrome Informing the Eular Recommendations for the Management of Behçet’s…
Abstract Number: 1285 • 2016 ACR/ARHP Annual Meeting
PET/CT Imaging in Patients with Vascular Behcet Disease
Bahtiyar Toz¹, Burak Erer¹, Sevil Kamali¹, Murat Inanc², Lale Ocal³ and Ahmet Gul¹, ¹Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ²Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, İstanbul, Turkey, ³Department of Internal Medicine, Rheumatology Division, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey
Background/Purpose: BehetÕs disease (BD) is a multisystemic disease characterized by recurrent inflammatory manifestations. BD is classified as variable vessel vasculitis. While inflammatory thrombotic venous findings…
Abstract Number: 3043 • 2016 ACR/ARHP Annual Meeting
Dense Genotyping of Immune Related Loci in a Multi-Ethnic Behçet’s Disease Cohort Identifies Genetic Associations in a Long Noncoding RNA Near QSOX2, RASIP1/FUT2, and IL12A-AS1
Paul Renauer¹, Patrick Coit¹, Travis Hughes², Mikhail Ognenovski¹, Adam Adler³, Lourdes Ortiz-Fernández⁴, Vuslat Yilmaz⁵, Kenan Aksu⁶, Nursen Duzgun⁷, Gokhan Keser⁸, Ayse Cefle⁹, Ayten Yazici¹⁰, Andac Ergen¹¹, Erkan Alpsoy¹², Carlo Salvarani¹³, Bruno Casali¹⁴, Ina Koetter¹⁵, Alexandra Zhernakova¹⁶, Cisca Wijmenga¹⁷, Fujio Takeuchi¹⁸, Shinji Harihara¹⁹, Toshikatsu Kaburaki²⁰, Yeong Wook Song²¹, Francisco David Carmona²², Marta E. Alarcon Riquelme²³, Javier Martín²², Güher Saruhan-Direskeneli²⁴, María Francisca Gonzalez Escribano²⁵, Haner Direskeneli²⁶ and Amr H Sawalha¹, ¹Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²Division of Health Sciences and Technology, Harvard Medical School, Boston, MA, ³Oklahoma Medical Research Foundation, OK, OK, ⁴Immunology department, Hospital Universitario Virgen del Rocío, Sevilla, Spain, ⁵Istanbul University, Istanbul Faculty of Medicine, Department of Physiology, Istanbul, Turkey, ⁶İnternal Medicine Division of Rheumatology, Ege University Medical Faculty, Izmir, Turkey, ⁷Internal Medicines, Rheumatology Department, Ankara University School of Medicine, Ankara, Turkey, ⁸Rheumatology, Ege University Medical Faculty, Izmir, Turkey, ⁹Rheumatology, Kocaeli University Faculty of Medicine, Kocaeli, Turkey, ¹⁰Rheumatology, Kocaeli University School of Medicine, Kocaeli, Turkey, ¹¹Okmeydaný Research and Education Hospital, Istanbul, Turkey, ¹²Department of Dermatology, Akdeniz University School of Medicine, Antalya, Turkey, ¹³Rheumatology, Azienda Ospedaliera ASMN, Istituto di Ricovero e Cura a Carattere Scientifico, Reggio Emilia, Italy, ¹⁴Molecular Biology Laboratory, Azienda Ospedaliera Arcispedale Santa Maria Nuova, Istituto di Ricovero e Cura a Carattere Scientifico, Reggio Emilia, Italy, ¹⁵Internal Medicine IV Rheumatology, Asklepios Klinik Altona, Hamburg, Germany, ¹⁶Rheumatology and Clinical Immunology, University of Groningen, University Medical Center, Groningen, Netherlands, ¹⁷Genetics, University Medical Hospital Groningen, University of Groningen, Groningen, Netherlands, ¹⁸#504 Lab/ Dep of Internal Medicine (Allergy & Rheumatology), Faculty of Medicine, University of Toyko, Tokyo, Japan, ¹⁹Division of Anthropology, Department of Biological Science, The University of Tokyo Graduate School of Science, Tokyo, Japan, ²⁰Ophthalmology, The University of Tokyo School of Medicine, Bunkyo-ku, Japan, ²¹Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, South Korea, ²²Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, PTS-Granada, Granada, Spain, ²³Centro de Genomica e Investigación Oncológica, Pfizer-University of Granada-Junta de Andalucía, Granada, Spain, ²⁴Department of Physiology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey, ²⁵Hospital Universitario Virgen del Rocío (IBiS,CSIC,US), Sevilla, Spain, ²⁶Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey
Background/Purpose: Behçet’s disease is a chronic relapsing inflammatory disease characterized by recurrent mucocutaneous involvement. We performed dense genotyping in immune related loci in a large…
Abstract Number: 2034 • 2016 ACR/ARHP Annual Meeting
Novel Susceptible Genes for Behçet’s Disease Identified By Dense Genotyping of Immune-Related Loci Implicate Host Responses to Microbial Exposure
Masaki Takeuchi^1,2, Nobuhisa Mizuki³, Akira Meguro⁴, Michael J. Ombrello⁵, Yohei Kirino⁶, Colleen Satorius⁷, Julie Le¹, Mary Blake⁸, Burak Erer⁹, Tatsukata Kawagoe², Duran Ustek¹⁰, Ilknur Tugal-tutkun¹¹, Emire Seyahi¹², Yilmaz Ozyazgan¹³, Inês Sousa¹⁴, Fereydoun Davatchi¹⁵, Vânia Francisco¹⁴, Farhad Shahram¹⁶, Bahar Abdollahi¹⁷, Abdolhadi Nadji¹⁷, Niloofar Shafiee¹⁷, Fahmida Ghaderibarmi¹⁸, Shigeaki Ohno¹⁹, Atsuhisa Ueda⁶, Yoshiaki Ishigatsubo²⁰, Massimo G. Gadina²¹, Sofia Oliveira¹⁴, Ahmet Gul⁹, Daniel L. Kastner¹ and Elaine F. Remmers²², ¹National Human Genome Research Institute, Bethesda, MD, ²Yokohama City University Graduate School of Medicine, Yokohama, Japan, ³Yokohama City University, Yokohama, Japan, ⁴Department of Ophthalmology and Visual Science, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ⁵Translational Genetics and Genomics Unit, NIAMS, NIH, Bethesda, MD, ⁶Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ⁷NIAMS, N.I.H, Bethesda, MD, ⁸National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁹Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ¹⁰Istanbul University, Istanbul, Turkey, ¹¹Department of Ophthalmology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey, ¹²Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ¹³Ophthalmology, Istanbul University, Cerrahpasa Medical Faculty, Department of Ophthalmology, Istanbul, Turkey, ¹⁴Universidade de Lisboa, Lisboa, Portugal, ¹⁵Internal Medicine, Rheumatology Research Ctr-Tehran Univ, Tehran, Iran, ¹⁶Tehran University of Medical Sciences, Tehran, Iran (Islamic Republic of), ¹⁷Tehran University of Medical Sciences, Teheran, Iran (Islamic Republic of), ¹⁸Tehran University of Medical Sciences, Teheran, Portugal, ¹⁹Hokkaido University Graduate School of Medicine, Hokkaido, Japan, ²⁰Int. Med. & Clin. Immunology, Yokohama City Grad Sch of Med, Yokohama, Japan, ²¹Translational Immunology Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²²National Human Genome Research Institute, National Institutes of Health, Bethesda, MD
Background/Purpose: Recent genetic studies have identified multiple susceptibility loci for Behçet’s disease. However, these genetic factors do not fully explain the apparent disease heritability.The purpose…
Abstract Number: 2144 • 2016 ACR/ARHP Annual Meeting
Functional Analysis of Macrophages in BehçEt’s Disease: C-C Chemokine Receptor Type 1 (CCR1) and IL-10 Are Implicated in Pathogenesis of the Disease
Hiroto Nakano¹, Yohei Kirino¹, Momoko Ohno¹, Kana Higashitani¹, Mitsuhiro Takeno², Ryusuke Yoshimi¹ and Hideaki Nakajima³, ¹Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ²Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ³Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan
Background/Purpose: The recent GWAS and subsequent studies have identified susceptible genes such as CCR1 and IL10 genes, suggesting pathological roles of macrophages in Behçet's disease…
Abstract Number: 2150 • 2016 ACR/ARHP Annual Meeting
Autoimmune Uveitis : Potential Role of Interleukin-22 (IL-22) in Pathogenesis
El-Desouki Fouda¹, El-Sayed Mostafa Elewah², Mona Elrayes³, Ghada Fouda⁴ and Mohamed Ahmed Bakry⁵, ¹Al-Azhar University, Dokki Cairo, Egypt, ²Opthalmology, Faculty of Medicine, Al-Azhar University, Cairo, Egypt, ³Clinical Pathology, Faculty of Medicine, Al-Azhar University, Cairo, Egypt, ⁴Faculty of Medicine, Al-Azhar University, Cairo, Egypt, ⁵Al-Azhar University, Allergy & Immunology Center, Cairo, Egypt
Background/Purpose: : IL-22 is a member of IL-10 family, with both anti- inflammatory and pro- inflammatory functions, orchestrating the immune and inflammatory response.IL-22 is secreted…
Abstract Number: 2940 • 2016 ACR/ARHP Annual Meeting
Bechet’s Disease and Sleep Quality in Korean Patients
Chang-Nam Son¹, Ji Min Lee¹, Hye-Jin Jeong², Ji-Min Kim¹, Sang-Hyon Kim¹, Sung Soo Kim³ and Seung-Hyeon Bae⁴, ¹Division of Rheumatology, Department of Internal Medicine, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, Korea, The Republic of, ²Division of Rheumatology, Department of Internal Medicine, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, South Korea, ³Division of Rheumatology, Department of Internal Medicine, Ulsan University School of Medicine, GangNeung Asan Hospital, Gangneung, South Korea, ⁴Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea
Background/Purpose: The purpose of this study was to find out the effects of sleep quality on Behcet’s disease in Korean population. We also investigated the…
Abstract Number: 2941 • 2016 ACR/ARHP Annual Meeting
Optimization of Adalimumab on Refractory Uveitis of Behcet’s Syndrome. Multicenter Study of 23 Patients
Carlos Fernández-Díaz¹, Ricardo Blanco¹, Vanesa Calvo-Río¹, Javier Loricera¹, J. Sanchez-bursón², Norberto Ortego Centeno³, Jose L. García Serrano⁴, Miguel Cordero⁵, J. Vazquez⁶, Emma Beltran⁷, Elia Valls⁸, O. Maiz Alonso⁹, Ana Blanco¹⁰, Ignacio Torre¹¹, Angel García-Aparicio¹², F.j Toyos-saénz¹³, L. Martinez-Costa¹⁴, Lucia C. Domínguez-Casas¹, Natalia Palmou¹ and Miguel Angel Gonzalez-Gay¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ²Rheumatology, Hospital Valme, Hospital Valme, Sevilla, Spain, ³Medicine Department, Hospital Universitario San Cecilio, Granada, Spain, ⁴Ophthalmology, Hospital Universitario San Cecilio, Granada, Spain, ⁵Ophthalmology, Hospital de León, León, Spain, ⁶Rheumatology, Hospital de Ferrol, Ferrol, Spain, ⁷Rheumatology, Hospital General Universitario de Valencia, Valencia, Spain, ⁸Rheumatology, Hospital Dr. Peset., Valencia, Spain, ⁹Rheumatology, Hospital Donostia, San Sebastian, Spain, ¹⁰Ophthalmology Department. Donostia University Hospital, Donostia, Spain, ¹¹Rheumatology, Hospital de Basurto, Bilbao, Spain, ¹²Rheumatology, Ophthalmology and rheumatology, Hospital de Ferrol, Ferrol, Ferrol, Spain, ¹³Rheumatology,, Hospital Virgen de la Macarena, Sevilla, Spain, ¹⁴Hospital Dr. Peset., Valencia, Spain
Background/Purpose: In non-infectious no anterior uveitis, adalimumab (ADA) is the only biologic drug that has shown efficacy in phase III randomized, double blind studies,…
Abstract Number: 2945 • 2016 ACR/ARHP Annual Meeting
Systematic Review: “Efficacy and Safety of Biological Versus Immunosuppressive Therapy Compared to Placebo in the Treatment of Uveitis Associated with BehçEt’s Disease.”
Ana Urruticoechea-Arana¹, Tatiana Cobo-Ibáñez², Virginia Villaverde García³, Montserrat Santos-Gómez⁴, Kelly Vargas Osorio⁵, Federico Díaz-González⁶, Leslie Fariñas Padrón⁵, Vanesa Calvo-Río⁷ and Ricardo Blanco Alonso⁷, ¹Hospital Can Misses, Ibiza, Spain, ²Hospital Universitario Reina Sofía, Universidad Europea de Madrid, Madrid, Spain, ³Rheumatology, Hospital Universitario de Móstoles, Móstoles, Spain, ⁴Rheumatology, Hospital Can Misses, Ibiza, Spain, ⁵Family and Community Medicine, Hospital Can Misses, Ibiza, Spain, ⁶Rheumatology, Hospital Universitario de Canarias, S/C Tenerife, Spain, ⁷Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain
Background/Purpose:
Abstract Number: 2947 • 2016 ACR/ARHP Annual Meeting
Adalimumab Versus Infliximab in Cystoid Macular Edema of Uveitis Associated to BehçEt Disease. Multicenter Study of 34 Patients
Lucia Cristina Domínguez-Casas¹, Vanesa Calvo-Río¹, Ricardo Blanco², Carlos Fernández-Díaz¹, Paz Rodríguez-Cundín³, Emma Beltran⁴, Marisa Hernández-Garfella⁵, Jose M Herreras⁶, Miguel Cordero-Coma⁷, Marina Mesquida⁸, Alfredo Adan⁹, M. Victoria Hernández¹⁰, David Diaz-Valle¹¹, Ignacio Torre-Salaberri¹², Manuel Díaz-Llopis¹³, Roberto Gallego¹⁴, Olga Maiz-Alonso¹⁵, Santos Insua¹⁶, Félix Francisco¹⁷, Raquel Almodóvar González¹⁸, Oscar Ruiz Moreno¹⁹, Fernando Jiménez-Zorzo²⁰, Javier Manero²¹, Myriam Gandía²², Joan Miquel Nolla²³, Nuria Vegas-Revenga²⁴, Natalia Palmou-Fontana¹ and Miguel Angel Gonzalez-Gay¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ²Rheumatology Department. Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Preventive Medicine, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ⁴Rheumatology, Hospital General Universitario de Valencia, Valencia, Spain, ⁵Ophtamology, Hospital General Universitario de Valencia, Valencia, Spain, ⁶Ophthalmology, Hospital Universitario, IOBA, Valladolid, Spain, ⁷Ophthalmology, Hospital de León, León, Spain, ⁸Ophthalmology, Hospital Clinic. Barcelona. Spain, Barcelona, Spain, ⁹Ophthalmology, Hospital Clinic de Barcelona,, Barcelona, Spain, ¹⁰Rheumatology, Hospital Clinic. Barcelona. Spain, Barcelona, Spain, ¹¹Ophthalmology Department, Hospital Clínico San Carlos, Madrid, Spain, ¹²Rheumatology, Hospital de Basurto, Bilbao, Spain, ¹³Hospital Universitario La Fe, Valencia, Spain, ¹⁴Ophtalmology, Hospital Universitario La Fe, Valencia, Spain, ¹⁵Hospital Universitario Donostia, Donostia, Spain, ¹⁶Rheumatology, Hospital Universitario Santiago de Compostela, La Coruña, Spain, ¹⁷Rheumatology, Hospital Doctor Negrín, Las Palmas de Gran Canaria, Spain, ¹⁸Rheumatology Unit, Hospital Universitario Fundación Alcorcón, Madrid, Spain, ¹⁹Ophthalmology and Rheumatology., Hospital Miguel Servet, Zaragoza, Spain, ²⁰Hospital Miguel Servet, Zaragoza, Spain, ²¹Rheumatology, Hospital Miguel Servet, Zaragoza, Spain, ²²Rheumatology, Hospital Puerta del Mar, Cadiz, Spain, ²³Rheumatology, Department of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ²⁴Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain
Background/Purpose: Cystoid macular edema (CME) is the most serious complication of uveitis and the most common cause of blindness in uveitis. Our aim was…
Abstract Number: 2948 • 2016 ACR/ARHP Annual Meeting
Fecal Calprotectin Level Is Useful in Identifying Active Disease in Behçet’s Syndrome Patients with Gastrointestinal Involvement: A Controlled Study
Sinem Nihal Esatoglu¹, Ibrahim Hatemi², Yesim Ozguler³, Gulen Hatemi³, Hafize Uzun⁴, Aykut Ferhat Celik⁵ and Hasan Yazici³, ¹Rheumatology, Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²Istanbul University, Cerrahpasa Medical School, Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Gastroenterology, Istanbul, Turkey, ³Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ⁴Biochemistry, Istanbul University, Cerrahpasa Medical School, Department of Biochemistry, Istanbul, Turkey, ⁵Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Gastroenterology, Istanbul, Turkey
Background/Purpose: The fecal calprotectin (FC) is widely used as a non-invasive method for identifying patients with active Crohn’s disease (CD) and ulcerative colitis. Gastrointestinal involvement…

« Previous Page
1
…
4
5
6
7
8
…
12
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].